Resident
Pool, Andrew, B.Kin, PharmD
Residency Program
BC Cancer
Project Title
An Examination of Olaparib Dose Adjustments in Patients with Advanced Ovarian Cancer
Investigators
James Conklin, B.Sc.(Pharm), ACPR, Winnie Cheng, B.Sc.(Pharm), Schaff, Kimberly (RPhT)
Abstract
Olaparib, a poly ADP-ribose polymerase (PARP) inhibitor, is a novel therapy used for extending the disease-free interval, and in maintenance therapy, of patients with ovarian cancer. This study examines the prescribing patterns of olaparib with a focus on dose modifications and how adverse drug effects impact prescribing patterns. We also examined prescribing practices between patients using Olaparib as first-line maintenance therapy versus those treated for relapse. 96 patient charts were included in the final analysis, which showed that one-third of patients will have a dose reduction. Adverse drug effects were common, with hematologic effects commonly attributed to delays in treatment.
